ProQR Therapeutics Stock Forecast, Price & News

ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

Is ProQR Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ProQR Therapeutics stock.
View analyst ratings for ProQR Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than ProQR Therapeutics?

Wall Street analysts have given ProQR Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ProQR Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for ProQR Therapeutics.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.03. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.80 million.
View ProQR Therapeutics' earnings history.

How has ProQR Therapeutics' stock price been impacted by COVID-19?

ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PRQR shares have increased by 6.3% and is now trading at $7.44.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for PRQR?

6 equities research analysts have issued 12 month price objectives for ProQR Therapeutics' shares. Their forecasts range from $18.00 to $44.00. On average, they anticipate ProQR Therapeutics' share price to reach $27.67 in the next year. This suggests a possible upside of 271.9% from the stock's current price.
View analysts' price targets for ProQR Therapeutics or view top-rated stocks among Wall Street analysts.

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the following people:

• Daniel Anton de Boer, Chief Executive Officer
• Smital Shah, Chief Financial & Business Officer
• Aniz Girach, Chief Medical Officer
• Jennifer Pluim, Vice President-Medical Affairs
• Naveed K. Shams, Chief Scientific Officer

Who are some of ProQR Therapeutics' key competitors?

Some companies that are related to ProQR Therapeutics include Protagonist Therapeutics (PTGX), Enanta Pharmaceuticals (ENTA), NGM Biopharmaceuticals (NGM), PureTech Health (PRTC), Centessa Pharmaceuticals (CNTA), Day One Biopharmaceuticals (DAWN), Zealand Pharma A/S (ZEAL), Bicycle Therapeutics (BCYC), Vectura Group (VEGPF), Organogenesis (ORGO), uniQure (QURE), Madrigal Pharmaceuticals (MDGL), Nurix Therapeutics (NRIX), Xenon Pharmaceuticals (XENE) and Generation Bio (GBIO).
View all of PRQR's competitors.

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.43%).

Which institutional investors are selling ProQR Therapeutics stock?

PRQR stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A..

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $7.44.

How much money does ProQR Therapeutics make?

ProQR Therapeutics has a market capitalization of $373.53 million and generates $10.80 million in revenue each year. The biopharmaceutical company earns $-53.19 million in net income (profit) each year or ($1.06) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

ProQR Therapeutics employs 1,504 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is www.proqr.com.

Where are ProQR Therapeutics' headquarters?

ProQR Therapeutics is headquartered at Zernikedreef 9, Leiden P7, 2333 CK.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at [email protected].